Spectral AI has received UK Conformity Assessed (UKCA) authorisation for its DeepView AI-Burn predictive software.

The authorisation allows the system to aid in burn wound diagnosis within the UK.

Spectral AI CEO Wensheng Fan said: “The completion of this milestone will allow us to sell our DeepView System in the UK and we expect to swiftly deploy six devices in the UK for customer evaluation and to begin generating revenue in the second half of this year.

“In addition, this regulatory authorisation opens up the ability to expand partnerships with regions such as the Middle East that recognise the UKCA authorisation.” 

The authorisation is expected to contribute to the company’s revenue, with commercialisation in the UK anticipated in the second half of 2024. This is in addition to the $28m revenue guidance communicated by Spectral AI previously.

The DeepView System features AI algorithms to analyse patient wounds and assess clinically validated data points.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This helps differentiate between healthy and damaged tissue in a short period.

The technology is claimed to have a 92% accuracy rate.

Currently, DeepView AI-Burn is indicated for use in individuals aged 18 and above.

Spectral AI is planning to expand the technology use to the paediatric population and is initiating case studies and series with surgeons at leading burn centres.

Spectral AI UK subsidiary executive vice-president Paul Chadwick said: “The authorisation of the DeepView System could effectively obviate the need for these long observation periods, accelerating the way we manage burn wounds in the UK.”

Last year, Spectral AI secured the UKCA mark and Class 1 medical device classification from the US Food and Drug Administration (FDA) for its DeepView SnapShotWound Imaging System.